RecruitingPhase 2NCT06386315

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Reduced Dose Hypofractionated Radiotherapy (3Gy x 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial


Sponsor

Mayo Clinic

Enrollment

112 participants

Start Date

May 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.


Eligibility

Min Age: 18 Years

Inclusion Criteria13

  • Age ≥ 18 years
  • Histological confirmation of indolent B-cell lymphoma that can include any of the following:
  • Follicular lymphoma (grade 1 or 2 or 3A)
  • Marginal zone lymphoma (nodal or extranodal)
  • Follicle center lymphoma
  • Any stage disease
  • Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3
  • Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
  • Provide written informed consent
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items
  • Confirmation from radiation oncologist of suitability to participate in study

Exclusion Criteria7

  • Any of the following:
  • Pregnant women
  • Nursing women
  • Women of childbearing potential who are unwilling to employ adequate contraception
  • T-cell lymphoma
  • Receiving treatment for small and chronic lymphocytic lymphoma
  • Grade 3B follicular lymphoma

Interventions

PROCEDUREComputed Tomography

Undergo CT or PET/CT

PROCEDUREEndoscopic Procedure

Undergo endoscopy

RADIATIONInvolved-site Radiation Therapy (3 Fractions)

Undergo ISRT in 3 fractions

RADIATIONInvolved-site Radiation Therapy (12 Fractions)

Undergo ISRT in 12 fractions

PROCEDUREPositron Emission Tomography

Undergo PET/CT

OTHERQuestionnaire Administration

Ancillary studies


Locations(7)

Mayo Clinic in Arizona

Scottsdale, Arizona, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

Mayo Clinic Health System in Albert Lea

Albert Lea, Minnesota, United States

Mayo Clinic Health System - Mankato

Mankato, Minnesota, United States

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Mayo Clinic Health System-Eau Claire Clinic

Eau Claire, Wisconsin, United States

Mayo Clinic Health System-Franciscan Healthcare

La Crosse, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06386315


Related Trials